Prolight Diagnostics (PRLD) Q2 2025 earnings summary

Executive summary

• Achieved key milestones in commercializing a point-of-care (POC) diagnostic platform, with the high-sensitivity troponin test as the first product launch.

• Initial results from a whole blood study confirmed equivalence with plasma, supporting regulatory approval efforts and partner discussions.

• Financial position strengthened by a fully subscribed SEK 100.3 million rights issue, enabling continued development and regulatory studies.

• Record interest from global commercial partners and successful showcasing of the Psyros prototype at an international congress.

Financial highlights

• Net sales remained at SEK 0 for both Q2 and the first half of 2025.

• Other operating income rose to SEK 946k in Q2 (from SEK 18k) and SEK 2.6m in H1 (from SEK 86k), mainly from UK government grants.

• Profit after tax was SEK -12.7m in Q2 (vs. -11.2m) and SEK -23.7m in H1 (vs. -20.2m).

• Earnings per share before and after dilution: SEK -0.02 in Q2 (unchanged), SEK -0.03 in H1 (improved from -0.04).

• Cash flow from operating activities: SEK -4.7m in Q2 (vs. -88k), SEK -13.9m in H1 (vs. -8.9m).

Outlook and guidance

• Capital raised from the rights issue will fund completion of product development, intensify commercial partner discussions, and initiate regulatory clinical performance studies in 2025.

• Continued focus on commercializing the Psyros POC system and expanding its diagnostic applications.